Loading…
The Progressive Course of Neurological Symptoms in Anterior Choroidal Artery Infarcts
Background Infarctions of the anterior choroidal artery affect multiple anatomical structures, leading to a wide spectrum of neurological deficits with frequent symptom fluctuation or progression. Aims To assess etiological mechanisms, frequency, and predicttorsof symptom progression, as well as its...
Saved in:
Published in: | International journal of stroke 2015-01, Vol.10 (1), p.134-137 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Background
Infarctions of the anterior choroidal artery affect multiple anatomical structures, leading to a wide spectrum of neurological deficits with frequent symptom fluctuation or progression.
Aims
To assess etiological mechanisms, frequency, and predicttorsof symptom progression, as well as its impact on prognosis.
Methods
Anterior choroidal artery infarct patients were prospectively identified via predefined infarct locations with ischemic lesions ⩾1·5 cm vertical diameter in cerebral imaging. Definition of neurological progression was ⩾2 National Institutes of Health Stroke Scale points in motor function or ⩾4 in total National Institutes of Health Stroke Scale. Stroke etiology was determined according to Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification. We assessed demographical data, risk factors, and acute phase parameters in order to find predictors of neurological progression.
Results
Thirty patients fulfilled the inclusion criteria. Eighteen patients (60%) had neurological progression during days 1–3. Despite similar stroke severity at admission (median National Institutes of Health Stroke Scale in progressive infarcts 4·5 versus 4; P = 0·72), patients with progression had more severe deficits at day 3 (median National Institutes of Health Stroke Scale 9 vs. 3·5; P = 0·04) and worse three-month outcome. Only 31% of patients with progression scored |
---|---|
ISSN: | 1747-4930 1747-4949 |
DOI: | 10.1111/j.1747-4949.2012.00953.x |